Edition:
United States

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.78USD
4:00pm EDT
Change (% chg)

$0.01 (+0.56%)
Prev Close
$1.77
Open
$1.79
Day's High
$1.79
Day's Low
$1.70
Volume
127,576
Avg. Vol
121,982
52-wk High
$2.70
52-wk Low
$1.00

DRRX.OQ

Chart for DRRX.OQ

About

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $243.13
Shares Outstanding(Mil.): 137.36
Dividend: --
Yield (%): --

Financials

  DRRX.OQ Industry Sector
P/E (TTM): -- 39.80 37.05
EPS (TTM): -0.21 -- --
ROI: -72.11 -5.86 14.35
ROE: -199.70 -4.70 15.56

BRIEF-Durect says PDUFA date for remoxy NDA of Sept 25 unchanged

* Says prescription drug user fee act (PDUFA) date for remoxy NDA of September 25, 2016 is unchanged

Jul 01 2016

BRIEF-Durect Corp announces FDA advisory committee meeting for remoxy

* Date for advisory committee meeting is August 5, 2016 and no change to PDUFA date of September 25, 2016 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 19 2016

BRIEF-Durect Corporation Q1 revenue $3.6 million

* Durect corporation announces first quarter 2016 financial results and update of programs

May 05 2016

BRIEF-Durect announces pricing of public offering of common stock

* Durect announces pricing of public offering of common stock

Apr 26 2016

BRIEF-Durect licensee, Pain Therapeutics resubmitts NDA for Remoxy to U.S. FDA

* Durect announces resubmission of Remoxy New Drug Application to the U.S. Food and Drug Administration

Mar 29 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Wright Reports
$75.00
Provider : S&P Capital IQ Quantitative Report
$104.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.